These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29403064)

  • 1. Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa.
    Siddik AB; Haas A; Rahman MS; Aralaguppe SG; Amogne W; Bader J; Klimkait T; Neogi U
    Sci Rep; 2018 Feb; 8(1):2363. PubMed ID: 29403064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
    Kalu AW; Telele NF; Aralaguppe SG; Gebre-Selassie S; Fekade D; Marrone G; Sonnerborg A
    Curr HIV Res; 2018; 16(2):113-120. PubMed ID: 29766813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
    Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
    Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Gracias S; El Yaalaoui I; Visseaux B; Charpentier C; Descamps D; Martin C; Lermechain F; Plantier J-C; Alessandri-Gradt E
    Microbiol Spectr; 2024 Jul; 12(7):e0389523. PubMed ID: 38809042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.
    Gupta S; Neogi U; Srinivasa H; Banerjea AC; Shet A
    J Acquir Immune Defic Syndr; 2014 Apr; 65(4):397-404. PubMed ID: 24189148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
    Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
    J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.
    Ceresola ER; Nozza S; Sampaolo M; Pignataro AR; Saita D; Ferrarese R; Ripa M; Deng W; Mullins JI; Boeri E; Tambussi G; Toniolo A; Lazzarin A; Clementi M; Canducci F
    J Antimicrob Chemother; 2015 May; 70(5):1391-5. PubMed ID: 25608585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
    Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
    Vandekerckhove L; Verhofstede C; Demecheleer E; De Wit S; Florence E; Fransen K; Moutschen M; Mostmans W; Kabeya K; Mackie N; Plum J; Vaira D; Van Baelen K; Vandenbroucke I; Van Eygen V; Van Marck H; Vogelaers D; Geretti AM; Stuyver LJ
    J Antimicrob Chemother; 2011 Feb; 66(2):265-72. PubMed ID: 21196489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.
    Matume ND; Tebit DM; Bessong PO
    AIDS Res Ther; 2020 Feb; 17(1):5. PubMed ID: 32033571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort.
    Kalu AW; Telele NF; Gebreselasie S; Fekade D; Abdurahman S; Marrone G; Sönnerborg A
    BMC Infect Dis; 2017 Jan; 17(1):37. PubMed ID: 28061826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.
    Poveda E; Alcamí J; Paredes R; Córdoba J; Gutiérrez F; Llibre JM; Delgado R; Pulido F; Iribarren JA; García Deltoro M; Hernández Quero J; Moreno S; García F
    AIDS Rev; 2010; 12(3):135-48. PubMed ID: 20842202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.
    Aralaguppe SG; Winner D; Singh K; Sarafianos SG; Quiñones-Mateu ME; Sönnerborg A; Neogi U
    J Med Virol; 2017 Jan; 89(1):106-111. PubMed ID: 27328744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V3 net charge: additional tool in HIV-1 tropism prediction.
    Montagna C; De Crignis E; Bon I; Re MC; Mezzaroma I; Turriziani O; Graziosi C; Antonelli G
    AIDS Res Hum Retroviruses; 2014 Dec; 30(12):1203-12. PubMed ID: 25322170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.
    Surdo M; Alteri C; Puertas MC; Saccomandi P; Parrotta L; Swenson L; Chapman D; Costa G; Artese A; Balestra E; Aquaro S; Alcaro S; Lewis M; Clotet B; Harrigan R; Valdez H; Svicher V; Perno CF; Martinez-Picado J; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2015 Jan; 21(1):103.e1-6. PubMed ID: 25636934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.